The untold story of Glenmark's phenomenal success in building a brand, Telma, which has 16 brand extensions and a combined turnover of Rs 1036 crore.
Glenmark’s Telma brand, which contains Telmisartan, has become well-known for treating hypertension and heart failure and preventing heart attacks and strokes.
The HBR case study traces the inception to the rise of Telma, the flagship brand of Glenmark Pharmaceuticals. Telma based on the molecular formulation Telmisartan was introduced by Glenmark in 2003 at a time when the most preferred and market-leading molecule for treating hypertension was Ramipril.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
